Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
Dihesys Digital Health Systems GmbH is currently addressing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and 4 distinct art units, showing a relatively broad distribution of work for a portfolio of this size. This variety suggests that the company's technology spans multiple specialized areas within the broader field, requiring a versatile prosecution strategy.
JOHN WILLIAM LIPPERT is the busiest examiner for the company, managing 2 busiest examiner pending office actions. This examiner handles a portion of the 5 pending office actions, while the remaining actions are distributed among the other 4 distinct examiners. This concentration makes the relationship with this specific examiner a high priority for the company's legal team. The outcome of these 2 busiest examiner pending office actions will heavily influence the overall success of the current docket.
The involvement of 4 distinct art units indicates that the 5 pending office actions are subject to different internal policies and technical standards within the USPTO. With 4 distinct examiners, the company must manage multiple prosecution timelines and styles. The pending office actions assigned to JOHN WILLIAM LIPPERT represent the most significant point of contact in the current docket. Practitioners must balance the needs of the 4 distinct examiners to ensure consistent progress across the entire portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 2 | 58.2% | +40.0% |
| GROUX, JENNIFER LILA | 1 | 34.8% | +39.3% |
| KAMM, JUDITH MARIE | 1 | 43.5% | +56.6% |
| COUGHLIN, DANIEL F | 1 | 39.0% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 73d overdue |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | KAMM, JUDITH MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 73d overdue |
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | LIPPERT, JOHN WILLIAM | 60d overdue |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | COUGHLIN, DANIEL F | 40d |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | KAMM, JUDITH MARIE | — |
| 17615450 | Pharmaceutical Dosage Forms and Method For Their Production | LIPPERT, JOHN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1754 | 1 |
| 1611 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258742 | Method For Producing Patient-Optimised Dosage Forms | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 60d overdue | Pending | Oct 12, 2023 |
| 17783818 | Dot Printing Method And Device For Additive Manufacturing Of Dosage Forms Which Contain Active Substances | GROUX, JENNIFER LILA | 1754 | §103§112 | Final Rejection | 73d overdue | Pending | Dec 14, 2022 |
| 17615431 | Additive Method For 3D Printing Active Ingredient-Containing Objects | KAMM, JUDITH MARIE | 1611 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2022 |
| 17615450 | Pharmaceutical Dosage Forms and Method For Their Production | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | — | Pending | Nov 30, 2021 |
| 17615559 | Polyvalent Dosage Forms and Method For Their Production | COUGHLIN, DANIEL F | 1619 | §103 | Non-Final OA | 40d | Pending | Nov 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial